Rejuvenation Technologies
Tuesday, June 04, 2024
Company Presentation
![Regenerative Medicine](https://cdn.asp.events/CLIENT_BIO_7BB99CBA_BAD1_B8C8_CF9F25DA29A80CC6/sites/BIOIC-2024/media/icons/seminars/blank.png)
Company Presentation Theater 3
Rejuvenation Technologies is extending telomeres using telomerase RNA to treat age-related diseases. Our pipeline includes respiratory, hepatic, and hematopoietic deficiency indications. We recently received over $5M in grants including a $4M grant from the California Institute of Regenerative Medicine (CIRM) to extend telomeres to treat pulmonary fibrosis. Since being launched from Stanford University the founders have developed highly efficient and well-tolerated delivery vehicles for delivering mRNA and circular RNA to extra-hepatic targets. We are on track to begin clinical trials in 2025.
![Rejuvenation Technologies](https://www.abstractscorecard.com/uploads/Tasks/upload/21754/XDQDGWMO-1752493-1-JPG(1).png)
Company Website:
http://rejuvenationtech.com
Lead Product in Development:
RNA/LNP biologics to extend telomeres to treat pulmonary fibrosis, liver disease, hematopoietic deficiency respectively
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Company HQ City
Mountain View
Company HQ State
CA
Company HQ Country
United States
CEO/Top Company Official
John Ramunas
Development Phase of Primary Product
Pre-Clinical
Primary Speaker